Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Talis Biomedical Corporation (TLIS : OTC)

• Company Description    Talis Biomedical Corporation engaged in developing and commercializing products for infectious diseases at the point-of-care. The company involved in developing the Talis One platform, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis Biomedical Corporation is based in MENLO PARK, Calif. Number of Employees: 99

• Price / Volume Information    Yesterday's Closing Price: $1.43 Daily Weekly Monthly 20 Day Moving Average: 452 shares Shares Outstanding: 1.82 (millions) Market Capitalization: $2.61 (millions) Beta: 1.29 52 Week High: $9.35 52 Week Low: $1.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.42% -2.38% 12 Week -15.88% -29.25% Year To Date -18.70% -23.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1375 WEST FULTON MARKET SUITE 700 - CHICAGO,IL 60607 USA ph: 650-433-3000 fax: - ir@talisbio.com https://talisbio.com

• General Corporate Information    Officers Robert J. Kelley - Chief Executive Officer and Member of the Rebecca L. Markovich - Interim Chief Financial Officer Rustem F. Ismagilov - Director Kimberly J. Popovits - Director Matthew L. Posard - Director Peer Information Talis Biomedical Corporation (CORR.) Talis Biomedical Corporation (RSPI) Talis Biomedical Corporation (CGXP) Talis Biomedical Corporation (BGEN) Talis Biomedical Corporation (GTBP) Talis Biomedical Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87424L207 SIC: 3826 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/24 Next Expected EPS Date: 08/18/25 Share - Related Items Shares Outstanding: 1.82 Most Recent Split Date: 7.00 (0.07:1) Beta: 1.29 Market Capitalization: $2.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/18/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.05 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 41.23% vs. Previous Quarter: 32.03% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©